City Therapeutics: Bloomberg reported half of IPO orders received no shares, top 10 investors taking 90%.
City Therapeutics IPO debuts 27% above $18 offer after upsized $200M deal
- City Therapeutics priced an upsized 11.1 million share IPO at $18 late Thursday for $200 million.
- Nasdaq trading began Friday under CTY, with the prior close set at the IPO price.
- Most of the 26.6% gain occurred at the open; last price $22.79 was slightly below open.
- Bloomberg reported half of IPO orders received no shares, with top 10 investors taking 90%.
- The RNAi biotech, chaired by former Alnylam CEO John Maraganore, is in Phase 1 for thrombosis.
- No other news or filings appeared after the pricing announcement the prior evening.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.